Novartis says Votubia receives EU approval for new indication

ZURICH (Reuters) - Novartis has broaded the indications for its Votubia drug, the company said on Tuesday, when the European Union approved its use to treat refractory partial-onset seizures in patients with tuberous sclerosis complex.